Cboe UK DKK

Novo Nordisk A/S (NOVOBC.XC)

531.60

+11.00

+(2.11%)

At close: June 13 at 2:12:09 PM GMT+1

Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out.

Novo Nordisk the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company after a year of decline that ultimately led to the firing of its CEO last month. Novo’s market capitalization is now $367 billion, pushing it above German software giant SAP’s $363 billion. On Friday, Novo stock was up as much as 2% in Denmark.

Barrons.com yesterday

NVO

LLY
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Zacks yesterday

LLY

NVO
NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for obesity, to phase III development.

Zacks yesterday

NVO

LLY
Company News for Jun 13, 2025

Companies In The News Are: ORCL, GOOGL, BA, NVO.

Zacks yesterday

GOOG

BA

NVO
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

Novo Nordisk is making moves to retain its market share in the weight loss space.

Clinical Trials Arena yesterday

NVO

GLDAF
Trending tickers: Boeing, Adobe, Exxon, Oracle and Novo Nordisk

The latest investor updates on stocks that are trending on Friday

Yahoo Finance UK 2 days ago

ORCL

ING

NONOF
Novo Nordisk regains crown as Europe's most valuable company

LONDON (Reuters) -Drugmaker Novo Nordisk (NVO) is once again Europe's largest company by market capitalisation, rising above German software firm SAP on Friday.

Reuters 2 days ago

NVO
Why Novo Nordisk Stock Pumped Higher on Thursday

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw its share price improve by nearly 3% on the day after it reported the results of a late-stage clinical trial. Novo Nordisk reported that it is advancing amycretin to a phase 3 study.

Motley Fool 2 days ago

NVO
Why Novo Nordisk (NVO) Outpaced the Stock Market Today

Novo Nordisk (NVO) concluded the recent trading session at $81.05, signifying a +2.95% move from its prior day's close.

Zacks 2 days ago

NVO
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year

The decision to advance the trials is based on feedback received from regulatory authorities in interactions following the end of its mid-stage trials, the company said. Amycretin, the Danish drugmaker's next-generation obesity drug, has a dual-mode action. Like its popular weight-loss drug Wegovy, amycretin not only mimics the gut hormone GLP-1, but also the effect of a hunger-suppressing pancreatic hormone called amylin.

Reuters 2 days ago

NVO
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management. “We are very pleased that the feedback from regulatory authorities has allowed

GlobeNewswire 2 days ago

NONOF

NVO
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Pharmaceutical Technology 2 days ago

NVO
4 Dividend Stocks to Double Up on Right Now

The stock market is a place where people tend to panic when things go on sale. Instead, buy the dip on these four fabulous dividend winners.

Motley Fool 2 days ago

GOOG

LMT

NVO
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:NVO) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity. Under the terms of the agreement, Deep Apple will discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual scr

Benzinga 3 days ago

NVO
NVO Stock Gains After Parvus Asset Management Builds Stake

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline buzz.

Zacks 3 days ago

NVO
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.

Zacks 3 days ago

LLY

NVO
Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Yahoo Finance 3 days ago

HIMS

LLY

NONOF
Nvidia Teams With Novo Nordisk to Supercharge Early-Stage Drug R&D

Novo Nordisk to Use Nvidia AI Tools in Pharma Research Push

GuruFocus.com 3 days ago

NVDA

NVO
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple

Deep Apple discovers drug candidates using its AI-based platform that screens virtual libraries of billions of compounds to cut drug discovery time, the company said. Under the deal, Novo will receive exclusive global rights to develop and commercialize so-called non-incretin oral therapies, which belong to a different class of medicines than its popular weight-loss and diabetes drugs Wegovy and Ozempic. Novo has been trying to strengthen its foothold in the potential $150 billion weight-loss drug market through the development of next-generation treatments as well as acquisitions and partnerships.

Reuters 3 days ago

NVO
The cheap fat jabs sending big pharma into a frenzy

For many Americans who tuned in to watch the Super Bowl earlier this year, it was a surprise to find themselves fat-shamed during the ad break.

The Telegraph 4 days ago

LLY

NVO

Performance Overview

Return	NOVOBC.XC	OMX Copenhagen 25 Index (^OMXC25)
YTD	-14.91%	+1.93%
1-Year	-45.27%	-9.62%
3-Year	+44.08%	+11.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOVOBC.XC)

Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out.

Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?

NVO Stock up on Plans to Advance Obesity Candidate Amycretin

Company News for Jun 13, 2025

Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

Trending tickers: Boeing, Adobe, Exxon, Oracle and Novo Nordisk

Novo Nordisk regains crown as Europe's most valuable company

Why Novo Nordisk Stock Pumped Higher on Thursday

Why Novo Nordisk (NVO) Outpaced the Stock Market Today

Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

4 Dividend Stocks to Double Up on Right Now

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

NVO Stock Gains After Parvus Asset Management Builds Stake

Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?

Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to

Nvidia Teams With Novo Nordisk to Supercharge Early-Stage Drug R&D

Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple

The cheap fat jabs sending big pharma into a frenzy

Performance Overview